Promising Potential of Zipalertinib Drives Buy Rating for Cullinan Management

Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Cullinan Management (CGEM – Research Report) and keeping the price target at $35.00.

Sean Laaman has given his Buy rating due to a combination of factors that highlight the promising potential of Cullinan Management’s therapeutic candidate, Zipalertinib. The REZILIENT1 results presented at ASCO demonstrated encouraging efficacy, particularly in patients who have been heavily pre-treated, including those who have undergone treatment with amivantamab. The clinical benefits observed, such as a 30% overall response rate and a median duration of response of 14.7 months in post-amivantamab patients, underscore the drug’s potential impact.
Moreover, the Key Opinion Leader (KOL) emphasized Zipalertinib’s favorable safety profile and its convenience as an oral treatment, which is seen as a significant advantage over intravenous options like amivantamab. The KOL also noted the unmet need for more tolerable treatments and the potential for Zipalertinib to differentiate itself from competitors due to its side-effect profile and familiarity among U.S. providers. These factors, along with the ongoing development and expected data from upcoming studies, contribute to the positive outlook and Buy rating for Cullinan Management’s stock.